01—Abstract
Summary
Summary of the 10-K filed March 26, 2002. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported a net loss of $36.9 milliona, or $1.42 per share, for the fiscal year ended December 31, 2001, compared with a net loss of $28.8 million, or $1.30 per share, in 2000.
Total revenues rose to $41.2 millionb from $14.6 million, driven mainly by the Taisho and GSK collaborations, while research and development expense increased to $74.3 million from $40.2 million. The company stated it does not expect to be profitable in 2002 and had an accumulated deficit of $107.4 million at year-end. It has no approved products; all of its product candidates are in research or clinical development.
The lead program is NBI-34060, a GABA-A agonist for insomnia in Phase III trials, with the first Phase III study begun in November 2001 and an planned program of approximately 3,300 additional subjects in eight large trials. Other clinical programs include NBI-34041, a CRF R1 antagonist in Phase I with GlaxoSmithKline, NBI-3001 (IL-4 fusion toxin) for malignant glioma and other cancers, and altered peptide ligands for multiple sclerosis and Type 1 diabetes. Cash, cash equivalents and short-term investments totaled $320.0 millionc at December 31, 2001, following a December 2001 public offering of 4.0 million shares that generated net proceeds of $175.6 million.
The company states that existing resources, together with interest income and future alliance payments, will be sufficient for at least the next twelve months. Janssen notified the company in March 2002 that it had terminated its 1995 and 1999 agreements, returning exclusive rights to the first generation CRF R1 antagonist compounds to Neurocrine, and the company does not expect additional payments under those agreements. The company reported no material legal proceedings.
02—Key points
Key Highlights
- Net loss of $36.9 million ($1.42 per share) for 2001, up from $28.8 million ($1.30 per share) in 2000; accumulated deficit of $107.4 million
- Total revenues of $41.2 million in 2001 versus $14.6 million in 2000, primarily from the Taisho and GSK collaborations
- Research and development expense rose to $74.3 million from $40.2 million, reflecting advancement of clinical programs
- Lead insomnia candidate NBI-34060 entered Phase III; first Phase III trial of approximately 500 patients commenced November 2001 within a program of about 3,300 subjects in eight trials
- Cash, cash equivalents and short-term investments of $320.0 million at December 31, 2001, after a December 2001 public offering of 4.0 million shares with net proceeds of $175.6 million
- Company does not expect to be profitable in 2002 and states existing capital resources are sufficient for at least the next twelve months
- Janssen terminated its 1995 and 1999 CRF antagonist agreements in March 2002, returning exclusive rights to first generation compounds to Neurocrine; no further Janssen payments expected
03—Questions
Frequently Asked Questions
What is Neurocrine's most advanced product candidate?
NBI-34060, a GABA-A agonist for insomnia, is the company's lead program and is in Phase III clinical trials. The company describes it as more potent and more selective than marketed non-benzodiazepines such as Ambien and Sonata, and states that Phase II studies showed no next-day residual sedation. The filing also notes risk that these results may not be confirmed in later trials.
Does Neurocrine have any products approved or generating product sales?
No. The filing states the company has not generated revenues from product sales and has not yet completed development, including regulatory approval, of any products. Its revenues in 2001 came from collaborations, milestones and license fees, and grants.
What drove the increase in revenue in 2001?
The increase was primarily due to the Taisho and GSK collaborations, which were effective in July 2000 and July 2001 respectively. The company recognized $16.6 million under the Taisho agreement and $19.2 million under the GSK agreement, which included a $15.5 million milestone achievement.
How well funded is the company and will it need more capital?
At December 31, 2001, cash, cash equivalents and short-term investments totaled $320.0 million. The company believes existing resources, together with interest income and future alliance payments, will be sufficient for at least the next twelve months, but it states it may require additional funding and may seek equity or debt financing, which could be dilutive.
What was the effect of Janssen's March 2002 termination?
Janssen terminated its 1995 and 1999 agreements, and exclusive rights to the first generation CRF R1 antagonist compounds reverted to Neurocrine. The company stated it does not expect any additional payments under the Janssen agreements, including the $3.5 million milestone that had been deferred.
04—Continue